1
|
Amado CA, Martín-Audera P, Agüero J, Lavín BA, Guerra AR, Boucle D, Ferrer-Pargada D, Berja A, Martín F, Casanova C, García-Unzueta M. Circulating levels of mitochondrial oxidative stress-related peptides MOTS-c and Romo1 in stable COPD: A cross-sectional study. Front Med (Lausanne) 2023; 10:1100211. [PMID: 36844198 PMCID: PMC9944395 DOI: 10.3389/fmed.2023.1100211] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/16/2022] [Accepted: 01/23/2023] [Indexed: 02/10/2023] Open
Abstract
Background MOTS-c and Romo1 are mitochondrial peptides that are modulated by oxidative stress. No previous studies have explored circulating levels of MOTS-c in patients with chronic obstructive pulmonary disease (COPD). Methods We enrolled 142 patients with stable COPD and 47 smokers with normal lung function in an observational cross-sectional study. We assessed serum levels of both MOTS-c and Romo1 and associated these findings with clinical characteristics of COPD. Results Compared with smokers with normal lung function, patients with COPD had lower levels of MOTS-c (p = 0.02) and higher levels of Romo1 (p = 0.01). A multivariate logistic regression analysis revealed that above-median MOTS-c levels were positively associated with Romo1 levels (OR 1.075, 95% CI 1.005-1.150, p = 0.036), but no association was found with other COPD characteristics. Below-median levels of circulating MOTS-c were associated with oxygen desaturation (OR 3.25 95% CI 1.456-8.522, p = 0.005) and walking <350 meters (OR 3.246 95% CI 1.229-8.577, p = 0.018) in six-minute walk test. Above-median levels of Romo1 were positively associated with current smoking (OR 2.756, 95% CI 1.133-6.704, p = 0.025) and negatively associated with baseline oxygen saturation (OR 0.776 95% CI 0.641-0.939, p = 0.009). Conclusions Reduced levels of circulating MOTS-c and increased levels of Romo1 were detected in patients diagnosed with COPD. Low levels of MOTS-c were associated with oxygen desaturation and poorer exercise capacity using 6 min walk test. Romo1 was associated with current smoking and baseline oxygen saturation. Trial registration www.clinicaltrials.gov; No.: NCT04449419; URL: www.clinicaltrials.gov. Date of registration: June 26, 2020.
Collapse
Affiliation(s)
- Carlos A. Amado
- Department of Pulmonology, Hospital Universitario Marqués de Valdecilla, Santander, Spain,University of Cantabria, Santander, Spain,IDIVAL (Instituto de Investigación Biomédica de Cantabria), Santander, Spain,*Correspondence: Carlos A. Amado ✉
| | - Paula Martín-Audera
- Department of Clinical Biochemistry, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Juan Agüero
- Department of Pulmonology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Bernardo A. Lavín
- Department of Clinical Biochemistry, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Armando R. Guerra
- Department of Clinical Biochemistry, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | | | - Diego Ferrer-Pargada
- Department of Pulmonology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Ana Berja
- Department of Clinical Biochemistry, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Fernando Martín
- Unidad de Deshabituación Tabáquica (UDESTA), Servicio Cántabro de Salud, Santander, Spain
| | - Ciro Casanova
- Servicio de Neumología-Unidad de Investigación, Hospital Universitario La Candelaria, Universidad de La Laguna, San Cristóbal de La Laguna, Spain
| | - Mayte García-Unzueta
- University of Cantabria, Santander, Spain,Department of Clinical Biochemistry, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| |
Collapse
|
2
|
Amado CA, Martín-Audera P, Agüero J, Ferrer-Pargada D, Josa Laorden B, Boucle D, Berja A, Lavín BA, Guerra AR, Ghadban C, Muñoz P, García-Unzueta M. Alterations in circulating mitochondrial signals at hospital admission for COPD exacerbation. Chron Respir Dis 2023; 20:14799731231220058. [PMID: 38112134 PMCID: PMC10734331 DOI: 10.1177/14799731231220058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/31/2023] [Accepted: 11/21/2023] [Indexed: 12/20/2023] Open
Abstract
BACKGROUND Chronic obstructive pulmonary disease (COPD) exacerbation (ECOPD) alters the natural course of the disease. To date, only C-reactive protein has been used as a biomarker in ECOPD, but it has important limitations. The mitochondria release peptides (Humanin (HN), FGF-21, GDF-15, MOTS-c and Romo1) under certain metabolic conditions. Here, we aimed to evaluate the pathophysiologic, diagnostic and prognostic value of measuring serum mitochondrial peptides at hospital admission in patients with ECOPD. METHODS A total of 51 consecutive patients admitted to our hospital for ECOPD were included and followed for 1 year; in addition, 160 participants with stable COPD from our out-patient clinic were recruited as controls. RESULTS Serum FGF-21 (p < .001), MOTS-c (p < .001) and Romo1 (p = .002) levels were lower, and GDF-15 (p < .001) levels were higher, in patients with ECOPD than stable COPD, but no differences were found in HN. In receiver operating characteristic analysis, MOTS-c (AUC 0.744, 95% CI 0.679-0.802, p < .001) and GDF-15 (AUC 0.735, 95% CI 0.670-0.793, p < .001) had the best diagnostic power for ECOPD, with a diagnostic accuracy similar to that of C-RP (AUC 0.796 95% IC 0.735-0.848, p < .001). FGF-21 (AUC 0.700, 95% CI 0.633-0.761, p < .001) and Romo1 (AUC 0.645 95% CI 0.573-0.712, p = .001) had lower diagnostic accuracy. HN levels did not differentiate patients with ECOPD versus stable COPD (p = .557). In Cox regression analysis, HN (HR 2.661, CI95% 1.009-7.016, p = .048) and MOTS-c (HR 3.441, CI95% 1.252-9.297, p = .016) levels exceeding mean levels were independent risk factors for re-admission. CONCLUSIONS Most mitochondrial peptides are altered in ECOPD, as compared with stable COPD. MOTS-c and GDF15 levels have a diagnostic accuracy similar to C-RP for ECOPD. HN and MOTS-c independently predict future re-hospitalization.
Collapse
Affiliation(s)
- Carlos A Amado
- Department of Pulmonology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
- Department of Medicine and Psychiatry, University of Cantabria, Santander, Spain
- IDIVAL (Instituto de Investigación Biomédica de Cantabria), Santander, Spain
| | - Paula Martín-Audera
- Department of Clinical Biochemistry, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Juan Agüero
- Department of Pulmonology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Diego Ferrer-Pargada
- Department of Pulmonology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Begoña Josa Laorden
- Department of Pulmonology, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Daymara Boucle
- Department of Medicine and Psychiatry, University of Cantabria, Santander, Spain
- Department of Internal Medicine, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Ana Berja
- Department of Clinical Biochemistry, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Bernardo A Lavín
- Department of Clinical Biochemistry, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Armando R Guerra
- Department of Clinical Biochemistry, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| | - Cristina Ghadban
- IDIVAL (Instituto de Investigación Biomédica de Cantabria), Santander, Spain
| | - Pedro Muñoz
- IDIVAL (Instituto de Investigación Biomédica de Cantabria), Santander, Spain
- Management of Primary Care of Cantabria, Servicio Cántabro de Salud, Santander, Spain
| | - Mayte García-Unzueta
- Department of Medicine and Psychiatry, University of Cantabria, Santander, Spain
- Department of Clinical Biochemistry, Hospital Universitario Marqués de Valdecilla, Santander, Spain
| |
Collapse
|
3
|
Amado CA, García-Unzueta M, Agüero J, Martín-Audera P, Fueyo P, Lavín BA, Guerra AR, Muñoz P, Tello S, Berja A, Casanova C. Associations of serum sclerostin levels with body composition, pulmonary function, and exacerbations in COPD patients. Pulmonology 2022:S2531-0437(22)00131-3. [PMID: 35963832 DOI: 10.1016/j.pulmoe.2022.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/10/2022] [Revised: 06/07/2022] [Accepted: 06/08/2022] [Indexed: 11/27/2022] Open
Abstract
BACKGROUND In COPD, the bronchial epithelium shows a pathologically activated Wnt pathway. Sclerostin (SOST) is a secreted glycoprotein that is associated with bone metabolism and blocks the Wnt pathway. We hypothesized that low sclerostin levels might be associated with lung function and COPD exacerbations in patients. METHODS We studied 139 outpatients with stable COPD and normal kidney function. We assessed the serum levels of SOST and bone metabolism parameters, body composition, clinical characteristics and lung function at baseline. We followed the patients prospectively for 12 months after enrolment. Moderate exacerbations and hospital admissions were recorded during follow-up. RESULTS The serum SOST levels were 23.98±7.6 pmol/l (men: 25.5±7.7 pmol/l, women: 20.3±5.9 pmol/l (p < 0.001)). SOST showed correlations with age (r = 0.36), FFMI (r = 0.38), FEV1 (r = 0.27), DLCO (r = 0.39), 6MWD (r = 0.19) and CAT (r = -0.24). In multivariate linear regression analysis, only age (beta=0.264) and FFMI (beta=1.241) remained significant. SOST showed a significant negative correlation with serum phosphorus (r = -0.29). Cox proportional risk analysis indicated that patients in the lower tertile of SOST levels were at higher risk of moderate COPD exacerbation (HR 2.015, CI95% 1.136-3.577, p = 0.017) and hospital admission due to COPD (HR 5.142, CI95% 1.380-19.158, p = 0.015) than the rest of the patients. CONCLUSIONS SOST levels are associated with body composition and lung function in patients with COPD. Furthermore, lower SOST levels predict a higher risk of exacerbations and hospitalization.
Collapse
Affiliation(s)
- C A Amado
- Department of Pulmonology, Hospital Universitario Marqués de Valdecilla. Santander, Spain; University of Cantabria. Santander, Spain; IDIVAL (Instituto de Investigación Biomédica de Cantabria). Santander, Spain.
| | - M García-Unzueta
- University of Cantabria. Santander, Spain; Department of Biochemistry, Hospital Universitario Marqués de Valdecilla. Santander, Spain
| | - J Agüero
- Department of Pulmonology, Hospital Universitario Marqués de Valdecilla. Santander, Spain
| | - P Martín-Audera
- Department of Biochemistry, Hospital Universitario Marqués de Valdecilla. Santander, Spain
| | - P Fueyo
- University of Cantabria. Santander, Spain
| | - B A Lavín
- Department of Biochemistry, Hospital Universitario Marqués de Valdecilla. Santander, Spain
| | - A R Guerra
- Department of Biochemistry, Hospital Universitario Marqués de Valdecilla. Santander, Spain
| | - P Muñoz
- Servicio Cántabro de Salud. Santander, Spain
| | - S Tello
- Department of Pulmonology, Hospital Universitario Marqués de Valdecilla. Santander, Spain
| | - A Berja
- Department of Biochemistry, Hospital Universitario Marqués de Valdecilla. Santander, Spain
| | - C Casanova
- Servicio de Neumología-Unidad de Investigación, Hospital Universitario La Candelaria, Universidad de La Laguna, Tenerife, Spain
| |
Collapse
|
4
|
Abstract
UNLABELLED Although the molecular basis for the pathophysiology of non-alcoholic steatohepatitis (NASH) is poorly understood, we evaluate the hepatic gene expression of cytokines, chemokines, cell receptors, growth factors, intracellular transducers and extracellular communication proteins in liver tissue of obese patients (with and without NASH), and we determine the specific intrahepatic gene expression profiles associated with histological severe NASH.Thirty-eight obese patients with BMI > 35 were analyzed, who underwent bariatric surgery. Biopsy specimen samples were snap-frozen in liquid nitrogen. Hepatic gene expression was determined in liver biopsy specimens from 3 groups: a) obese patients without NASH (n = 12); b) patients with NASH without fibrosis (n = 13); and c) patients with NASH and fibrosis (n = 13). Genes were considered to be expressed differentially in NASH only if there was a greater than 2-fold difference in abundance of mRNA when compared with each of the control group. These results were confirmed by real-time PCR. Fourteen genes were differentially expressed (10 overexpressed and 4 underexpressed) in patients with NASH. Genes that were significantly overexpressed included prohibitin, TNF, TNF RI (p55), MCSF, R2-TRAIL, b1-CTGF, FGF, VEGF, and BIGH3OBR. Insulin growth factor-1, insulin growth factor-2, interleukin-2 and tyrosine-receptor were underexpressed in NASH patients. IN CONCLUSION 1. The obese patients with NASH without fibrosis show an overexpression of proinflammatory and proapoptotic genes. Also, the NASH patients with fibrosis show an overexpression of fibrogenic genes, including the leptin receptor Ob-Rb.2. The up-regulated gene expression of prohibitin suggests mitochondrial dysfunction in NASH patients.
Collapse
Affiliation(s)
- A Cayón
- Servicio de Aparato Digestivo, Hospital Universitario Marqués de Valdecilla, Santander
| | | | | | | |
Collapse
|